ERN1 and type 1 diabetes mellitus: Thus researchers speculate that there are salvageable beta cells during this “honeymoon period” that could be a promising target for the treatment of T1D with drugs that blunt the ABL-IRE1α or other UPR branches (Morita et al., 2017).